BioMimetix was founded in 2013 based on breakthrough science from Duke University to advance a platform of a new drug class, redox-active metalloporphyrins, which are small enzymatic molecules and optimized for redox activity at near diffusion limited rates.

BioMimetix’s robust clinical pipeline spanning oncology and dermatology indications are supported by demonstrated clinical efficiency in ongoing clinical studies as well as extensive preclinical data in solid tumors as well as inflammatory skin diseases.